arrow
P

Patricia Pozo-Rosich

vall d’hebron university hospital
H指数:52
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recommendations on key aspects of migraine prevention: A Delphi consensus among experts of the headache study group of the Spanish society of neurology (GECSEN)

关于偏头痛预防关键方面的建议:西班牙神经学会头痛研究组(GECSEN)专家的德尔菲共识

2026-11-160
OAAI
Migraine beyond attacks: Insights on the interictal phase

偏头痛发作间期:对间期阶段的见解

2026-11-030
PRE
Migraine

偏头痛

2026-10-070
PRE
A Global Perspective on Migraine Attack Triggers: Understanding Differences Across Lifestyles, Religions, and Regions

全球视角下的偏头痛发作诱因:理解生活方式、宗教和地区差异

2026-09-250
PRE
A multidisciplinary multicentric approach to the identification of predictive biomarkers of response to erenumab – the protocol of the phase 4, European, open-label controlled trial of the BIOMIGA project

多学科多中心方法用于识别对erenumab反应的预测生物标志物——BIOMIGA项目第4阶段、欧洲、开放标签对照试验的方案

2026-09-210
OA
Effectiveness of Rimegepant for the Acute Treatment of Migraine Among Participants Using Different Types of Preventive Therapy: Analyses from CONFIDENCE

利美卡 gepant 在使用不同类型预防性疗法患者中急性治疗偏头痛的有效性:CONFIDENCE 研究分析

2026-09-090
OAAI
Climate Change, Neurological Disorders and Brain Health: To-Know Concepts and Future Actions by the EAN Environmental Influences in Neurology Task Force

气候变化、神经系统疾病与脑健康:欧洲神经病学学会环境因素影响任务组应知概念与未来行动

2026-09-030
OAAI
EMHA migraine scoring system: A novel, valid, and reliable metric to capture severity, align with patients, and facilitate communication

EMHA偏头痛评分系统:一种用于捕捉严重程度、与患者保持一致并促进沟通的新型、有效且可靠的指标

2026-09-020
PRE
Evaluation of the effectiveness and safety of anti-CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO-CGRP study

评估抗CGRP单克隆抗体在偏头痛和自身免疫性疾病患者中的有效性与安全性:IMMUNO-CGRP研究

IF0
2026-04-010
OAAI
Transcultural headache medicine: A framework for integrating cultural contexts into headache science and care – a call to action from the International Headache Society

跨文化头痛医学:将文化背景整合到头痛科学与护理中的一个框架——国际头痛学会的行动倡议

2026-03-310
PRE
Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial

偏头痛患者中艾普尼珠单抗的持续疗效:针对先前预防性治疗失败且自报有精神科合并症的受试者的回顾性分析——安慰剂对照的DELIVER试验的后续分析

2026-02-110
OAAI
Moderate to Severe Acute Migraine Attacks: An Opinion Paper on the Use of Triptans and Triptan-NSAIDs Combinations in Individualized Treatment Plans

中度至重度急性偏头痛发作:关于三叉神经痛药物和三叉神经痛药物-非甾体抗炎药组合在个体化治疗计划中应用的论文

2025-12-180
OAAI
Combination preventive therapy with onabotulinumtoxinA and atogepant for chronic migraine: A 24-week, prospective, real-world evaluation (SYNERGY study)

联合ona-botulinumtoxinA和atogepant预防慢性偏头痛的治疗:一项为期24周、前瞻性、真实世界评估(SYNERGY研究)

2025-12-020
PRE
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response

阿托格匹兰坦在抗CGRP单克隆抗体治疗失败的偏头痛患者中的应用:一项关于疗效、安全性、持续性和应答预测因子的多中心真实世界研究

2025-11-280
OAAI